| scholarly article | Q13442814 |
| P50 | author | Peter Tontonoz | Q62569518 |
| Karin E. Bornfeldt | Q87887672 | ||
| Farah Kramer | Q125299327 | ||
| P2093 | author name string | Charles E Alpers | |
| Kelly L Hudkins | |||
| Jenny E Kanter | |||
| Jinkuk Choi | |||
| Anna Batorsky | |||
| P2860 | cites work | LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor | Q24656186 |
| Molecular mechanisms of diabetic kidney disease | Q27003963 | ||
| Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery | Q29615235 | ||
| The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial. | Q50867968 | ||
| Reducing VEGF-B Signaling Ameliorates Renal Lipotoxicity and Protects against Diabetic Kidney Disease. | Q51140451 | ||
| Genetic obesity unmasks nonlinear interactions between murine type 2 diabetes susceptibility loci. | Q51552683 | ||
| Mouse models of diabetic nephropathy | Q83665875 | ||
| Macrophage accumulation in human progressive diabetic nephropathy | Q83935710 | ||
| The pathobiology of diabetic complications: a unifying mechanism | Q29617766 | ||
| Leukocyte recruitment and vascular injury in diabetic nephropathy | Q30439127 | ||
| In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses | Q33327474 | ||
| Effects of lowering LDL cholesterol on progression of kidney disease | Q33974663 | ||
| Transgenic expression of dominant-active IDOL in liver causes diet-induced hypercholesterolemia and atherosclerosis in mice | Q33992107 | ||
| Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice | Q34142722 | ||
| BTBR Ob/Ob mutant mice model progressive diabetic nephropathy | Q34455365 | ||
| The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial | Q34630074 | ||
| The two-receptor model of lipoprotein clearance: tests of the hypothesis in "knockout" mice lacking the low density lipoprotein receptor, apolipoprotein E, or both proteins | Q35233650 | ||
| BTBR ob/ob mice as a novel diabetic neuropathy model: Neurological characterization and gene expression analyses | Q35558662 | ||
| FERM-dependent E3 ligase recognition is a conserved mechanism for targeted degradation of lipoprotein receptors | Q35647668 | ||
| Diabetes promotes an inflammatory macrophage phenotype and atherosclerosis through acyl-CoA synthetase 1. | Q35849515 | ||
| Myeloid Cell Prostaglandin E2 Receptor EP4 Modulates Cytokine Production but Not Atherogenesis in a Mouse Model of Type 1 Diabetes | Q36063184 | ||
| The phenotypes of podocytes and parietal epithelial cells may overlap in diabetic nephropathy | Q36299942 | ||
| Kidney disease and increased mortality risk in type 2 diabetes | Q36574770 | ||
| Lipid changes and statins in chronic renal insufficiency | Q36665911 | ||
| Stable liver-specific expression of human IDOL in humanized mice raises plasma cholesterol | Q36702427 | ||
| Reversibility of structural and functional damage in a model of advanced diabetic nephropathy | Q36977327 | ||
| Temporal trends in the prevalence of diabetic kidney disease in the United States | Q37064114 | ||
| Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis | Q37166321 | ||
| Diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: advances and contributions | Q37333543 | ||
| Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions | Q37486465 | ||
| Noninvasive imaging of retinal morphology and microvasculature in obese mice using optical coherence tomography and optical microangiography | Q37596809 | ||
| Altered renal lipid metabolism and renal lipid accumulation in human diabetic nephropathy | Q37603244 | ||
| Estimating podocyte number and density using a single histologic section | Q37733611 | ||
| Targeting inflammation in diabetic kidney disease: early clinical trials | Q38857166 | ||
| Executive Summary: Heart Disease and Stroke Statistics--2016 Update: A Report From the American Heart Association | Q40061255 | ||
| Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development | Q41088301 | ||
| Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease | Q41533607 | ||
| Induction of atherosclerosis in mice and hamsters without germline genetic engineering. | Q42228460 | ||
| Effect of lipid reduction on the progression of renal disease: a meta-analysis | Q43514434 | ||
| Atherosclerosis susceptibility differences among progenitors of recombinant inbred strains of mice. | Q44059065 | ||
| Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury | Q44692955 | ||
| Increase in serum amyloid a evoked by dietary cholesterol is associated with increased atherosclerosis in mice | Q44995472 | ||
| Macrophages in streptozotocin-induced diabetic nephropathy: potential role in renal fibrosis | Q45170289 | ||
| Blockade of CCL2/CCR2 signalling ameliorates diabetic nephropathy in db/db mice | Q45232179 | ||
| Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice | Q46865455 | ||
| Plasma Triglycerides and HDL-C Levels Predict the Development of Diabetic Kidney Disease in Subjects With Type 2 Diabetes: The AMD Annals Initiative. | Q50227786 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | type 2 diabetes | Q3025883 |
| atherosclerosis | Q12252367 | ||
| P577 | publication date | 2017-11-15 | |
| P1433 | published in | The American Journal of Pathology | Q4744259 |
| P1476 | title | A Novel Type 2 Diabetes Mouse Model of Combined Diabetic Kidney Disease and Atherosclerosis |
| Q89967822 | Monocytes and Macrophages as Protagonists in Vascular Complications of Diabetes |
| Q50102325 | Novel Reversible Model of Atherosclerosis and Regression Using Oligonucleotide Regulation of the LDL Receptor |
| Q92620845 | To Explore the Pathogenesis of Vascular Lesion of Type 2 Diabetes Mellitus Based on the PI3K/Akt Signaling Pathway |
Search more.